HECTD3

Across TCGA pan-cancer cohorts, HECTD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HECTD3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HECTD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HECTD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where HECTD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.660	0.429	<.001	85	view →
CCRCC	DFS	Median	II,III,IV	0.853	0.526	<.001	74	view →
UCEC	DFS	Tertile	All	0.922	1.000	.029	4	view →
HNSC	OS	Median	IV	0.915	0.763	.036	1	view →
LSCC	OS	Quartile	II,III,IV	0.625	0.919	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HECTD3–PDAC (OS)

Open the PDAC breakdown →